von Willebrand Disease

Slide 1 · von Willebrand Disease

From platelet adhesion to factor VIII protection

Vascular injury

vWF-mediated adhesion

Stable hemostasis

Inheritance • quantitative and qualitative defects • clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Explain why vWF participates in both primary and secondary hemostasis.

Distinguish quantitative deficiency from qualitative vWF dysfunction.

Connect type-specific mechanisms to bleeding patterns and laboratory findings.

Interpret focused clinical scenarios and treatment principles.

Slide 3 · Hemostasis requires coordinated components

Endothelium and subendothelial matrix define the injured vessel surface.

Platelets form the initial, mechanically fragile hemostatic plug.

Coagulation deposits fibrin to consolidate the platelet plug.

Von Willebrand factor connects the vessel wall, platelets, and factor VIII.

Schematic

Vessel injury

Platelet plug

Fibrin stabilization

Slide 4 · Primary hemostasis begins with adhesion

Vascular injury exposes subendothelial collagen and matrix-bound vWF.

Platelet GpIb/IX engages vWF anchored to the matrix.

This adhesive interaction recruits platelets to the injured surface.

Schematic

Subendothelial collagen / matrix

Platelet

GpIb

VWF

Adhesive bridge

Slide 5 · Platelet activation amplifies recruitment

Adherent platelets undergo shape change and granule release.

ADP and thromboxane A₂ recruit and activate additional platelets.

Activation increases the ability of GpIIb/IIIa to bind fibrinogen.

Schematic

Adhesion

Activation

Recruitment

Slide 6 · Aggregation uses a different molecular bridge

Fibrinogen links GpIIb/IIIa receptors on adjacent activated platelets.

This interaction produces platelet–platelet aggregation.

VWF-mediated adhesion and fibrinogen-mediated aggregation are complementary, not synonymous.

Feature

Adhesion

Aggregation

Bridge

VWF

Fibrinogen

Platelet receptor

GpIb/IX

GpIIb/IIIa

Target

Exposed matrix

Adjacent platelets

Slide 7 · Secondary hemostasis stabilizes the plug

Activated platelet surfaces support assembly of coagulation-factor complexes.

The factor IXa–VIIIa complex promotes activation of factor X.

Thrombin generation and fibrin deposition strengthen the initial plug.

Schematic

IXa + VIIIa

X → Xa

Thrombin → fibrin

Slide 8 · VWF operates across two hemostatic pathways

Adhesive function: Links platelets to exposed subendothelial matrix.

Carrier function: Binds and protects circulating factor VIII.

Disease may therefore display platelet-type bleeding with an altered intrinsic-pathway test.

Schematic

Von Willebrand factor

Matrix–platelet adhesion

Factor VIII stabilization

Slide 9 · Endothelial cells synthesize vWF

Endothelial cells release vWF into the circulation.

A fraction is deposited in the subendothelial matrix.

Deposited vWF is positioned to act immediately when the endothelial lining is disrupted.

Schematic

Endothelial synthesis

Plasma + matrix vWF

Injury-dependent adhesion

Slide 10 · Megakaryocytes supply platelet vWF

Megakaryocytes produce vWF stored in platelet α-granules.

Activation releases granule vWF near an injured vessel.

Released vWF can contribute to the local adhesive response.

Schematic

Megakaryocyte

Platelet α-granules

Local vWF release

Slide 11 · Circulating and matrix vWF have distinct locations

Circulating vWF carries factor VIII and can interact with exposed matrix.

Subendothelial vWF provides a ready-made adhesive interface.

The same protein consequently supports both plasma and vessel-wall functions.

Feature

Circulating pool

Subendothelial pool

Location

Plasma

Extracellular matrix

Key function

Factor VIII protection

Platelet attachment

Access

Continuous

Exposed by injury

Slide 12 · VWF is assembled into multimers

Individual vWF subunits are assembled into very large multimeric structures.

The largest forms provide particularly effective multivalent platelet interactions.

Disrupted assembly can impair function despite continued protein expression.

Schematic

Large multimer

Intermediate

Small

Relative multimer structure

Slide 13 · Multimer size matters for platelet capture

Multiple binding sites make high-molecular-weight vWF functionally effective.

Multivalent vWF helps form stable interactions under high shear stress.

Loss of large multimers diminishes efficient platelet adhesion.

Schematic

Large multimer

Absent

Intermediate

Absent

Small

Larger species missing (schematic)

Slide 14 · VWF is not a substitute for platelet receptors

GpIb deficiency prevents normal engagement with vWF.

GpIIb/IIIa deficiency disrupts a later aggregation step.

These inherited receptor disorders help localize the site of the defect.

Feature

GpIb defect

GpIIb/IIIa defect

Affected step

Adhesion

Aggregation

Ligand interaction

VWF

Fibrinogen

Named disorder

Bernard–Soulier

Glanzmann thrombasthenia

Slide 15 · VWF carries factor VIII in the bloodstream

Factor VIII and vWF associate in a large plasma complex.

Binding stabilizes factor VIII after secretion into the circulation.

Loss of vWF shortens factor VIII survival and may lower its measurable activity.

Schematic

Circulating vWF

Carrier for factor VIII

Adhesion at injury site

Slide 16 · Factor VIII binding greatly extends survival

A factor VIII half-life of approximately 2.4 hours without vWF protection.

Association with vWF increases the half-life to approximately 12 hours.

This explains why severe vWF deficiency can also resemble a coagulation-factor deficiency.

Feature

Without vWF protection

With vWF protection

Factor VIII half-life

≈ 2.4 hours

≈ 12 hours

Mechanism

Rapid loss

Binding and stabilization

Slide 17 · Factor VIII supports factor X activation

Factor VIII is a cofactor for factor IXa.

Their complex converts factor X toward factor Xa on activated platelet surfaces.

Fibrin generation is compromised when functional factor VIII is markedly reduced.

Schematic

IXa + VIIIa

Activation of X

Downstream fibrin

Slide 18 · Two defects explain a severe phenotype

Primary defect: Fewer effective platelet–matrix interactions.

Secondary contribution: Reduced factor VIII stability.

Severe forms can combine mucocutaneous bleeding with deeper hemorrhage.

Schematic

Severe vWF defect

Impaired primary plug

Impaired fibrin support

Slide 19 · VWD is a common inherited bleeding disorder

VWD as the most common inherited human bleeding disorder.

The text gives an approximate prevalence of 1% among United States adults.

Many affected persons have a relatively mild phenotype.

Slide 20 · Mild disease may remain unrecognized

Baseline hemostatic capacity may be sufficient for everyday minor injuries.

Surgery, tooth extraction, or other hemostatic stress can reveal the deficit.

Clinical recognition therefore depends on both baseline phenotype and challenge history.

Schematic

Mild baseline phenotype

Hemostatic challenge

Unexpected bleeding

Slide 21 · Epistaxis reflects mucosal vulnerability

Spontaneous nasal bleeding is a characteristic presentation.

The phenotype is consistent with impaired formation of the primary platelet plug.

Recurrent mucosal bleeding should prompt assessment beyond the platelet count.

Slide 22 · Excessive wound bleeding is an important clue

Persistent bleeding after cuts or tissue injury may be disproportionate.

The problem is defective hemostatic plugging rather than simply low platelet numbers.

A history of recurrent wound bleeding supports a primary hemostatic disorder.

Schematic

Tissue injury

Impaired adhesion

Persistent bleeding

Slide 23 · Heavy menstrual bleeding may be the first clue

Menorrhagia is a typical manifestation listed.

A mucosal bleeding history can be more informative than dramatic spontaneous deep hemorrhage.

Bleeding history should include menstrual and reproductive contexts when relevant.

Slide 24 · Inheritance is usually autosomal dominant

Most cases show autosomal dominant inheritance.

Autosomal recessive disease occurs in rarer, severe variants.

Pedigree patterns require interpretation alongside incomplete penetrance.

Feature

Often dominant

Rarely recessive

Common examples

Type 1; Type 2

Type 3

Typical expression

Variable

Often severe

Family pattern

Vertical transmission possible

Affected siblings possible

Slide 25 · Clinical severity varies among relatives

A single defective vWF allele may produce different bleeding phenotypes within a family.

Expression is influenced by circulating vWF concentrations.

A mildly affected relative does not exclude meaningful disease in another family member.

Slide 26 · Molecular heterogeneity complicates attribution

Hundreds of vWF sequence variants have been described.

Only a minority have been formally shown to cause disease.

A molecular finding must be interpreted in the context of phenotype and functional results.

Schematic

Sequence variant

Functional effect?

Clinical concordance?

Slide 27 · Three broad vWD types organize diagnosis

Type 1: Quantitative, partial loss of vWF.

Type 2: Qualitative vWF dysfunction, with recognized subtypes.

Type 3: Quantitative, near-complete vWF loss.

Approximately 70% type 1 cases and 25% type 2 cases.

Feature

Type 1

Type 2

Type 3

Primary defect

Partial quantity

Function

Near-absent quantity

General phenotype

Usually mild

Mild–moderate

Often severe

Inheritance

Usually AD

Usually AD

AR

Slide 28 · Quantity and quality must be distinguished

A low amount of protein can reduce total functional activity.

A normal amount of structurally abnormal protein may also show low activity.

Antigen and functional assays therefore address different diagnostic questions.

Schematic

Low vWF activity

Reduced protein quantity

Qualitative dysfunction

Slide 29 · Type 1: Partial quantitative deficiency

Type 1 has a mild to moderate reduction in circulating vWF.

It is generally associated with mild bleeding.

It accounts for about 70% of vWD cases.

Schematic

Large multimer

Intermediate

Small

Reduced circulating vWF quantity

Slide 30 · Type 1 can impair vWF maturation

Some point substitutions interfere with normal maturation of the protein.

The resulting reduction in available circulating vWF weakens platelet adhesion.

This is a production/processing explanation for a quantitative phenotype.

Schematic

Point substitution

Impaired maturation

Lower plasma vWF

Slide 31 · Type 1 can accelerate plasma clearance

Other mutations allow vWF production but shorten its time in circulation.

Accelerated clearance produces a low steady-state vWF concentration.

Different molecular mechanisms can converge on the same type 1 phenotype.

Schematic

Variant vWF secreted

Rapid plasma clearance

Reduced steady-state vWF

Slide 32 · Type 3: Recessive, near-absent vWF

Type 3 is usually autosomal recessive.

Deletions or frameshift variants involving both alleles can prevent meaningful synthesis.

Little or no vWF remains to support adhesion or factor VIII stability.

Schematic

Large multimer

Absent

Intermediate

Absent

Small

Absent

Near-absence of circulating vWF

Slide 33 · Type 3 also produces factor VIII deficiency

Without vWF, factor VIII is poorly stabilized in plasma.

Reduced factor VIII can impair the coagulation contribution to clot formation.

The combination explains the severe, hemophilia-like phenotype.

Schematic

Type 3 vWD

Very poor adhesion

Low factor VIII

Slide 34 · Severe vWD is not simply thrombocytopenia

Type 3 severity arises from extreme vWF loss and secondary factor VIII reduction.

Platelet counts may remain normal despite defective adhesion.

A normal count must not be interpreted as normal platelet-mediated hemostasis.

Feature

Measured quantity

Hemostatic function

Platelet count

Often normal

Adhesion impaired

VWF

Nearly absent

Adhesive bridge lost

Factor VIII

Reduced

Fibrin support reduced

Slide 35 · Type 2: Qualitative vWF dysfunction

Type 2 denotes defective function rather than simple lack of protein.

Some affected proteins are expressed but cannot perform normal adhesive tasks.

The type includes several molecular and functional subtypes.

Schematic

VWF protein present

Abnormal structure

Reduced functional activity

Slide 36 · Type 2A involves abnormal multimer assembly

Type 2A as the most common type 2 subtype.

Missense changes interfere with assembly of functional multimers.

Large and intermediate multimers are missing from plasma.

Schematic

Large multimer

Absent

Intermediate

Absent

Small

Larger species missing (schematic)

Slide 37 · Type 1 and type 2 need different interpretation

Type 1 mainly reduces the amount of available vWF.

Type 2 chiefly reduces the functional quality of vWF.

Activity alone may be decreased in both; Protein quantity helps distinguish them.

Feature

Type 1

Type 2

Mechanism

Quantitative

Qualitative

VWF quantity

Reduced

May be preserved

VWF activity

Reduced

Reduced

Clinical range

Usually mild

Mild–moderate

Slide 38 · Type 1 and type 3 differ in depth of loss

Both are quantitative disorders, but the magnitude of deficiency differs markedly.

Type 1 generally retains enough vWF for a milder phenotype.

Type 3 may leave negligible vWF and consequently substantial factor VIII deficiency.

Feature

Type 1

Type 3

Deficiency

Partial

Near-complete

Inheritance

Usually AD

AR

Severity

Usually mild

Often severe

Factor VIII

May decline

Often markedly reduced

Slide 39 · A focused bleeding history guides testing

Characterize epistaxis, wound bleeding, menorrhagia, and postoperative bleeding.

Ask whether bleeding occurred only after a substantial hemostatic challenge.

Document similar symptoms in relatives while accounting for variable expression.

Slide 40 · Normal platelet count does not exclude vWD

VWD produces a functional platelet-adhesion defect.

Platelet counts are typically normal.

Platelet counting and platelet-function assessment answer different questions.

Feature

Count

Function

Question

How many platelets?

Can platelets adhere?

In vWD

Usually normal

Abnormal

Why

Production preserved

VWF bridge defective

Slide 41 · PT and PTT evaluate different pathways

Prothrombin time (PT) evaluates extrinsic and common coagulation pathways.

Partial thromboplastin time (PTT) evaluates intrinsic and common pathways.

A vWF-related fall in factor VIII can affect PTT without requiring PT prolongation.

Feature

PT

PTT

Primary pathway

Extrinsic + common

Intrinsic + common

Factor VIII sensitive?

Not directly

Yes

Relevance to vWD

Usually not altered

Can be prolonged

Slide 42 · Why factor VIII loss can prolong PTT

The intrinsic coagulation assay depends on factor VIII activity.

VWF normally prolongs the circulating survival of factor VIII.

Marked vWF deficiency can reduce factor VIII sufficiently to prolong PTT.

Schematic

Reduced vWF

Reduced factor VIII

Prolonged PTT possible

Slide 43 · Antigen tests measure protein abundance

Immunologic assays quantify factor VIII and vWF protein levels.

VWF antigen addresses quantity rather than adhesive performance.

A quantitative result alone cannot fully classify a qualitative defect.

Schematic

VWF testing

Antigen → quantity

Functional test → activity

Slide 44 · Ristocetin testing probes vWF function

Patient plasma is combined with reagent platelets and ristocetin.

Ristocetin activates vWF-mediated binding to platelet GpIb/IX.

The extent of agglutination reflects functional plasma vWF activity.

Schematic

Patient plasma + platelets

Add ristocetin

Measure agglutination

Slide 45 · Reduced activity links the disease subtypes

Both reduced quantity and qualitative dysfunction can lower active vWF.

Reduced ristocetin cofactor activity as a characteristic finding.

Subtype interpretation requires combining activity with protein quantity and clinical context.

Feature

Type 1 / type 3

Type 2

Reason activity falls

Insufficient protein

Dysfunctional protein

Count

Normal platelets possible

Normal platelets possible

Next interpretation

Severity of deficiency

Quality of multimers

Slide 46 · Factor VIII assays add a second dimension

Coagulation-based factor VIII testing measures the factor’s functional capacity.

Low factor VIII may be secondary to loss of its vWF carrier.

This is particularly important when severe vWD resembles hemophilia.

Schematic

Lab evaluation

VWF antigen/activity

Factor VIII function

Slide 47 · Laboratory interpretation is multidimensional

Platelet number evaluates thrombocytopenia, not adhesive competence.

VWF antigen and function evaluate quantity and biological activity.

Factor VIII activity and PTT assess the secondary-coagulation contribution.

Schematic

Platelet count

VWF antigen + activity

Factor VIII / PTT

Slide 48 · Distinguish vWD from hemophilia A

VWD affects vWF-dependent platelet adhesion and may secondarily reduce factor VIII.

Hemophilia A arises from a primary factor VIII gene defect.

Mucosal predominance versus hemarthrosis and the vWF panel help localize the defect.

Feature

Von Willebrand disease

Hemophilia A

Primary defect

VWF

Factor VIII

Hemostatic limb

Adhesion ± coagulation

Coagulation

Clinical clue

Mucocutaneous

Deep tissue / joints

Inheritance

Usually autosomal

X-linked

Slide 49 · Acquired platelet dysfunction is another branch

Aspirin inhibits cyclooxygenase-mediated platelet responses.

Uremia may impair platelet adhesion, secretion, and aggregation.

These acquired mechanisms differ from inherited vWF quantitative or qualitative defects.

Feature

VWD

Acquired dysfunction

Example

Inherited vWF defect

Aspirin; Uremia

Primary mechanism

VWF adhesion impaired

Platelet signaling/response

Use in differential

Family + vWF assays

Exposure/comorbidity

Slide 50 · Desmopressin mobilizes endogenous vWF

Desmopressin as a stimulus for vWF release.

It may help selected individuals with type 1 or type 2 disease around procedures.

Its utility depends on the patient retaining a releasable functional vWF pool.

Schematic

Desmopressin

VWF release

Improved hemostatic support

Slide 51 · Concentrates directly replace deficient proteins

Plasma-derived concentrates can contain both vWF and factor VIII.

They may support platelet adhesion and secondary coagulation.

Use is described for hemostatic challenges in selected type 1 or 2 disease.

Schematic

Factor concentrate

Supplied vWF

Supplied factor VIII

Slide 52 · Recombinant vWF is a replacement option

The source identifies recombinant vWF as an alternative replacement product.

This strategy replaces the defective adhesive protein rather than releasing stores.

Therapy must be individualized rather than inferred from the type label alone.

Schematic

VWF replacement

Available functional vWF

Platelet adhesion support

Slide 53 · Type 3 requires sustained hemostatic protection

Severe type 3 disease has little or no endogenous vWF available.

Prophylactic replacement with plasma concentrates and factor VIII.

Prophylaxis addresses the risk of severe hemophilia-like bleeding.

Schematic

Type 3 vWD

Adhesive deficit

Factor VIII deficit

Slide 54 · Clinical case: Bleeding after dental extraction

A young adult reports prolonged bleeding after a tooth extraction.

There is recurrent epistaxis; Platelet count is reported as normal.

What shared defect could explain the mucosal and procedural bleeding?

Schematic

Clinical reasoning

?

Phenotype

?

Mechanism

?

Most likely subtype

Answer and reasoning on following slide

Slide 55 · Case interpretation: Investigate vWF function

A normal platelet count does not test the vWF–GpIb adhesive bridge.

Assess vWF activity and quantity rather than relying only on platelet number.

If factor VIII is reduced, intrinsic-pathway testing may also be abnormal.

Schematic

Bleeding history

VWF activity + antigen

Factor VIII / PTT

Slide 56 · Clinical case: Severe bleeding in siblings

Two siblings have severe bleeding and no detectable functional vWF.

Factor VIII activity is also reduced.

Which vWD category best explains both abnormalities?

Schematic

Clinical reasoning

?

Phenotype

?

Mechanism

?

Most likely subtype

Answer and reasoning on following slide

Slide 57 · Case interpretation: Near-absent vWF

Near-absent vWF supports a profound quantitative defect.

Reduced factor VIII follows from loss of plasma stabilization.

This mechanism supports the severe, hemophilia-like bleeding pattern of type 3.

Schematic

Near-absent vWF

Adhesion failure

Factor VIII loss

Slide 58 · Clinical case: Protein present but not effective

A patient has mild to moderate mucosal bleeding and reduced functional vWF.

Substantial protein is present, but larger multimers are lacking.

Which mechanistic type is most consistent with these findings?

Schematic

Clinical reasoning

?

Phenotype

?

Mechanism

?

Most likely subtype

Answer and reasoning on following slide

Slide 59 · Case interpretation: Type 2A multimer defect

Protein abundance alone does not establish functional adequacy.

Loss of large and intermediate multimers indicates abnormal assembly in the source description.

Activity and multimer pattern clarify why the adhesive system underperforms.

Schematic

Large multimer

Absent

Intermediate

Absent

Small

Larger species missing (schematic)

Slide 60 · Integrate type, phenotype, and laboratory results

Type 1: Partial deficiency, variable expression, usually mild phenotype.

Type 2: Qualitative dysfunction, including type 2A multimer defects.

Type 3: Near-absence, low factor VIII, often severe phenotype.

A normal platelet count does not contradict any of these mechanisms.

Feature

Type 1

Type 2

Type 3

Core problem

Low quantity

Poor quality

Near-zero quantity

Clinical pattern

Usually mild

Mild–moderate

Often severe

Mechanistic clue

Maturation/clearance

Multimer defect

Biallelic loss

Slide 61 · Essential clinicopathologic synthesis

VWF is the adhesive bridge between matrix and platelet GpIb/IX.

Its binding to factor VIII explains the coagulation component of severe disease.

Quantitative versus qualitative defects underlie the three major vWD types.

Clinical history, vWF activity/antigen, and factor VIII testing must be interpreted together.

Slide 62 · Source and further textbook context

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

Chapter 14: Red Blood Cell and Bleeding Disorders — factor VIII–vWF complex and vWD.

Chapter 4: Hemodynamic Disorders — platelet adhesion, aggregation, and hemostasis.